Epix President Andrew Uprichard: An Interview With "The Pink Sheet" DAILY
This article was originally published in The Pink Sheet Daily
Executive Summary
A day after Epix announces plans to further appeal two FDA "approvable" letters for Vasovist, Uprichard discusses why he's taking his case to CDER Director Steve Galson.
You may also be interested in...
Epix Pharmaceuticals President Andrew Uprichard: An Interview With “The Pink Sheet” DAILY
Uprichard discusses FDA’s recent encouraging response to Epix’s Vasovist appeal, the regulatory climate for imaging agents, and Epix’s conversion to therapeutics.
Epix Pharmaceuticals President Andrew Uprichard: An Interview With “The Pink Sheet” DAILY
Uprichard discusses FDA’s recent encouraging response to Epix’s Vasovist appeal, the regulatory climate for imaging agents, and Epix’s conversion to therapeutics.
Cipher To Appeal “Approvable” Letter for CIP-Isotretinoin
Toronto firm maintains agency’s request for additional clinical data has already been addressed in existing NDA package.